Recursion (RXRX) CEO Najat Khan Sells 22,408 Shares

What Happened
Najat Khan, CEO, President and a director of Recursion Pharmaceuticals (RXRX), sold 22,408 shares in an open-market transaction on September 8, 2026. The weighted-average sale price was $3.52 per share, for total proceeds of approximately $78,822. This was a sale (not a purchase or option exercise).

Key Details

• Transaction date: 2026-09-08 (reported on Form 4 filed 2026-09-10). Filing appears within the normal two-business-day SEC window.
• Transaction type: Open-market sale (code S).
• Shares sold: 22,408; weighted-average price: $3.52; total proceeds: ~$78,822.
• Price range: Trades executed at prices from $3.485 to $3.58; $3.52 is the weighted average (footnote indicates multiple trade prices).
• Footnotes: Transaction executed under a Rule 10b5-1 trading plan adopted Sept 22, 2025 (prearranged plan). The filer will provide a breakdown of the number of shares sold at each price upon request by SEC staff, the issuer, or a security holder.
• Shares owned after transaction: Not disclosed in the provided excerpt of the filing.

Context
Sales under 10b5-1 plans are pre-scheduled, which can indicate routine disposals for liquidity or diversification rather than a reaction to inside information. For retail investors, purchases generally signal stronger insider conviction than routine sales; this single sale is modest in dollar size and should be considered alongside other insider activity and fundamentals.